176 related articles for article (PubMed ID: 6091423)
1. Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.
Verstraete M
Agents Actions Suppl; 1984; 15():173-87. PubMed ID: 6091423
[No Abstract] [Full Text] [Related]
2. [The efficacy of ticlid in treating intermittent claudication in atherosclerotic stenosis of the arteries of the lower extremities].
Kirichenko AA; Prekina VI; Repinskaia NP; Novichkova IuN; Ter-Gevondian NM; Vinogradova IV
Ter Arkh; 1994; 66(12):23-6. PubMed ID: 7900036
[TBL] [Abstract][Full Text] [Related]
3. Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication.
Aukland A; Hurlow RA; George AJ; Stuart J
J Clin Pathol; 1982 Jul; 35(7):740-3. PubMed ID: 7047575
[TBL] [Abstract][Full Text] [Related]
4. [The effects of ticlopidine on platelet aggregation: study on 13 atherosclerotic patients].
Lenci R; Galante A; Borzi M; Ariganello M; Sommariva L; Filice A; Cannata D
Clin Ter; 1983 Feb; 104(3):205-9. PubMed ID: 6861457
[No Abstract] [Full Text] [Related]
5. [Platelet anti-aggregant drugs and ischemic cardiopathy: evaluation of the effect on platelet aggregation and on antithrombin III].
Avellone G; Mandalà V; Novo S; Pinto A; Riolo FP; Davì G; Raneli G
Boll Soc Ital Cardiol; 1981; 26(8):697-712. PubMed ID: 6289854
[No Abstract] [Full Text] [Related]
6. [Evaluation of oral drugs for intermittent claudication of the legs in phase III clinical trials. Options selected for the ACT study].
Destors JM; Arcan JC
Therapie; 1985; 40(6):451-8. PubMed ID: 4089787
[No Abstract] [Full Text] [Related]
7. [Status and trends in the field of inhibitors of thrombocyte function].
Glusa E
Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):575-9. PubMed ID: 6083929
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of platelet function by ticlopidine in arteriosclerosis obliterans of the lower limbs.
Davì G; Pinto A; Francavilla G; Paterna S; Campisi D; Strano A
Thromb Res; 1985 Oct; 40(2):275-81. PubMed ID: 2933846
[No Abstract] [Full Text] [Related]
9. Antiplatelet drugs in the management of patients with thrombotic disorders.
Harker LA
Semin Thromb Hemost; 1986 Apr; 12(2):134-55. PubMed ID: 3016905
[No Abstract] [Full Text] [Related]
10. [Role of the blood platelets in the atherosclerotic process and clinical use of a new drug, Suloctidil, with anti-aggregating activity].
Armani U; Piana A
Arch Maragliano Patol Clin; 1979; 35(2):57-62. PubMed ID: 233645
[No Abstract] [Full Text] [Related]
11. A double-blind trial of ticlopidine in sickle cell disease.
Semple MJ; Al-Hasani SF; Kioy P; Savidge GF
Thromb Haemost; 1984 Jul; 51(3):303-6. PubMed ID: 6388012
[TBL] [Abstract][Full Text] [Related]
12. A double-blind trial of suloctidil v. placebo in intermittent claudication.
Jones NA; De Haas H; Zahavi J; Kakkar VV
Br J Surg; 1982 Jan; 69(1):38-40. PubMed ID: 6274471
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effect of ticlopidine for ischemic leg ulcers.
Katsumura T
Agents Actions Suppl; 1984; 15():167-72. PubMed ID: 6385645
[No Abstract] [Full Text] [Related]
14. [Antiplatelet activity of picotamide in patients with chronic vascular pathology].
Coto V; Carrieri P; Cocozza M; Oliviero U; Picano T; Spinoli G; Cacciatore L
Minerva Cardioangiol; 1986 Sep; 34(9):601-4. PubMed ID: 2949164
[No Abstract] [Full Text] [Related]
15. Platelets and diabetic vascular disease.
Paton RC; Passa P
Diabete Metab; 1983 Dec; 9(4):306-12. PubMed ID: 6230270
[TBL] [Abstract][Full Text] [Related]
16. [Platelet aggregation inhibitors].
Castaigne A; Benghozi R; Bienvenu MP
Rev Infirm; 1981 Dec; 31(19):45-8. PubMed ID: 6977177
[No Abstract] [Full Text] [Related]
17. Platelet half-life in comparison to other in-vivo platelet function parameters such as thromboxane B2, beta-thromboglobulin and platelet factor 4 in patients with atherosclerotic lesions with and without hyperlipoproteinemia.
Strobl-Jäger E; Fitscha P; Kaliman J; Widhalm K; Sinzinger H
Vasa; 1986; 15(4):373-8. PubMed ID: 2948337
[No Abstract] [Full Text] [Related]
18. [Trapidil after one year].
Agus GB
Minerva Cardioangiol; 1993 May; 41(5):159-66. PubMed ID: 8373465
[TBL] [Abstract][Full Text] [Related]
19. Rationale for the use of antiplatelet drugs in patients with peripheral vascular disease.
Violi F; Balsano F
Clin Trials Metaanal; 1994 Apr; 29(1):81-7. PubMed ID: 10150187
[TBL] [Abstract][Full Text] [Related]
20. The influence of ticlopidine on the natural course of retinal vein occlusion.
Houtsmuller AJ; Vermeulen JA; Klompe M; Zahn KJ; Henkes HE; Baarsma GS; Tijssen J
Agents Actions Suppl; 1984; 15():219-29. PubMed ID: 6385648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
